CN110743035A - Preparation method and application of intelligent antibacterial hydrogel - Google Patents
Preparation method and application of intelligent antibacterial hydrogel Download PDFInfo
- Publication number
- CN110743035A CN110743035A CN201911074386.XA CN201911074386A CN110743035A CN 110743035 A CN110743035 A CN 110743035A CN 201911074386 A CN201911074386 A CN 201911074386A CN 110743035 A CN110743035 A CN 110743035A
- Authority
- CN
- China
- Prior art keywords
- solution
- hydrogel
- antibacterial
- vesicles
- bacteria
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000017 hydrogel Substances 0.000 title claims abstract description 45
- 230000000844 anti-bacterial effect Effects 0.000 title claims abstract description 31
- 238000002360 preparation method Methods 0.000 title claims abstract description 12
- 244000052616 bacterial pathogen Species 0.000 claims abstract description 23
- 241000894006 Bacteria Species 0.000 claims abstract description 21
- 238000001514 detection method Methods 0.000 claims abstract description 21
- 230000001954 sterilising effect Effects 0.000 claims abstract description 8
- 238000004659 sterilization and disinfection Methods 0.000 claims abstract description 7
- 239000000243 solution Substances 0.000 claims description 28
- 239000003242 anti bacterial agent Substances 0.000 claims description 25
- 206010052428 Wound Diseases 0.000 claims description 19
- 208000027418 Wounds and injury Diseases 0.000 claims description 19
- 230000001580 bacterial effect Effects 0.000 claims description 18
- BTXNYTINYBABQR-UHFFFAOYSA-N hypericin Chemical compound C12=C(O)C=C(O)C(C(C=3C(O)=CC(C)=C4C=33)=O)=C2C3=C2C3=C4C(C)=CC(O)=C3C(=O)C3=C(O)C=C(O)C1=C32 BTXNYTINYBABQR-UHFFFAOYSA-N 0.000 claims description 17
- 229940005608 hypericin Drugs 0.000 claims description 17
- PHOKTTKFQUYZPI-UHFFFAOYSA-N hypericin Natural products Cc1cc(O)c2c3C(=O)C(=Cc4c(O)c5c(O)cc(O)c6c7C(=O)C(=Cc8c(C)c1c2c(c78)c(c34)c56)O)O PHOKTTKFQUYZPI-UHFFFAOYSA-N 0.000 claims description 17
- SSKVDVBQSWQEGJ-UHFFFAOYSA-N pseudohypericin Natural products C12=C(O)C=C(O)C(C(C=3C(O)=CC(O)=C4C=33)=O)=C2C3=C2C3=C4C(C)=CC(O)=C3C(=O)C3=C(O)C=C(O)C1=C32 SSKVDVBQSWQEGJ-UHFFFAOYSA-N 0.000 claims description 17
- 239000003504 photosensitizing agent Substances 0.000 claims description 15
- 241000699670 Mus sp. Species 0.000 claims description 14
- 241000699666 Mus <mouse, genus> Species 0.000 claims description 13
- YUDPTGPSBJVHCN-VMMWWAARSA-N 4-methyl-7-[(2r,3s,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxychromen-2-one Chemical compound C1=CC=2C(C)=CC(=O)OC=2C=C1O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]1O YUDPTGPSBJVHCN-VMMWWAARSA-N 0.000 claims description 12
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 12
- 238000006911 enzymatic reaction Methods 0.000 claims description 12
- 230000002165 photosensitisation Effects 0.000 claims description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 10
- 229920001661 Chitosan Polymers 0.000 claims description 9
- 229920000858 Cyclodextrin Polymers 0.000 claims description 8
- 239000001116 FEMA 4028 Substances 0.000 claims description 8
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 claims description 8
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 claims description 8
- 235000011175 beta-cyclodextrine Nutrition 0.000 claims description 8
- 229960004853 betadex Drugs 0.000 claims description 8
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 8
- 238000002474 experimental method Methods 0.000 claims description 8
- 239000007787 solid Substances 0.000 claims description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 8
- 239000003795 chemical substances by application Substances 0.000 claims description 7
- KILNVBDSWZSGLL-KXQOOQHDSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC KILNVBDSWZSGLL-KXQOOQHDSA-N 0.000 claims description 6
- 239000007788 liquid Substances 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 6
- 230000029663 wound healing Effects 0.000 claims description 6
- 239000000284 extract Substances 0.000 claims description 5
- 230000012010 growth Effects 0.000 claims description 5
- 239000000203 mixture Substances 0.000 claims description 5
- 238000003756 stirring Methods 0.000 claims description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 4
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 claims description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 4
- CPLXHLVBOLITMK-UHFFFAOYSA-N Magnesium oxide Chemical compound [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 claims description 4
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 claims description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 4
- 239000002775 capsule Substances 0.000 claims description 4
- 235000012000 cholesterol Nutrition 0.000 claims description 4
- 150000002632 lipids Chemical class 0.000 claims description 4
- 239000011259 mixed solution Substances 0.000 claims description 4
- 238000011282 treatment Methods 0.000 claims description 4
- 239000008096 xylene Substances 0.000 claims description 4
- 238000006243 chemical reaction Methods 0.000 claims description 3
- 239000003153 chemical reaction reagent Substances 0.000 claims description 3
- 238000000502 dialysis Methods 0.000 claims description 3
- 239000000463 material Substances 0.000 claims description 3
- 239000012528 membrane Substances 0.000 claims description 3
- HSHNITRMYYLLCV-UHFFFAOYSA-N 4-methylumbelliferone Chemical compound C1=C(O)C=CC2=C1OC(=O)C=C2C HSHNITRMYYLLCV-UHFFFAOYSA-N 0.000 claims description 2
- 229920001817 Agar Polymers 0.000 claims description 2
- 108090000790 Enzymes Proteins 0.000 claims description 2
- 102000004190 Enzymes Human genes 0.000 claims description 2
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 claims description 2
- 238000012449 Kunming mouse Methods 0.000 claims description 2
- 239000001888 Peptone Substances 0.000 claims description 2
- 108010080698 Peptones Proteins 0.000 claims description 2
- 239000002253 acid Substances 0.000 claims description 2
- 239000008272 agar Substances 0.000 claims description 2
- 238000004458 analytical method Methods 0.000 claims description 2
- 238000010171 animal model Methods 0.000 claims description 2
- 235000015278 beef Nutrition 0.000 claims description 2
- 239000006059 cover glass Substances 0.000 claims description 2
- 230000018044 dehydration Effects 0.000 claims description 2
- 238000006297 dehydration reaction Methods 0.000 claims description 2
- 238000011033 desalting Methods 0.000 claims description 2
- 230000004069 differentiation Effects 0.000 claims description 2
- 239000012153 distilled water Substances 0.000 claims description 2
- 238000001035 drying Methods 0.000 claims description 2
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 claims description 2
- 238000011049 filling Methods 0.000 claims description 2
- 239000001963 growth medium Substances 0.000 claims description 2
- 239000012535 impurity Substances 0.000 claims description 2
- 238000004020 luminiscence type Methods 0.000 claims description 2
- 239000000395 magnesium oxide Substances 0.000 claims description 2
- 239000002609 medium Substances 0.000 claims description 2
- 230000007935 neutral effect Effects 0.000 claims description 2
- 229910052757 nitrogen Inorganic materials 0.000 claims description 2
- 235000019319 peptone Nutrition 0.000 claims description 2
- 150000003904 phospholipids Chemical class 0.000 claims description 2
- 239000004417 polycarbonate Substances 0.000 claims description 2
- 229920000515 polycarbonate Polymers 0.000 claims description 2
- 229920000642 polymer Polymers 0.000 claims description 2
- 238000007789 sealing Methods 0.000 claims description 2
- 238000002791 soaking Methods 0.000 claims description 2
- 239000011780 sodium chloride Substances 0.000 claims description 2
- 239000012192 staining solution Substances 0.000 claims description 2
- 239000008399 tap water Substances 0.000 claims description 2
- 235000020679 tap water Nutrition 0.000 claims description 2
- 238000012360 testing method Methods 0.000 claims description 2
- 239000000126 substance Substances 0.000 claims 1
- 238000005303 weighing Methods 0.000 claims 1
- 239000007850 fluorescent dye Substances 0.000 abstract description 4
- 230000004044 response Effects 0.000 abstract description 3
- 231100000699 Bacterial toxin Toxicity 0.000 abstract description 2
- 239000004599 antimicrobial Substances 0.000 abstract description 2
- 239000000688 bacterial toxin Substances 0.000 abstract description 2
- 244000052769 pathogen Species 0.000 abstract description 2
- 230000001717 pathogenic effect Effects 0.000 abstract description 2
- 208000035143 Bacterial infection Diseases 0.000 abstract 1
- 208000022362 bacterial infectious disease Diseases 0.000 abstract 1
- 230000003013 cytotoxicity Effects 0.000 abstract 1
- 231100000135 cytotoxicity Toxicity 0.000 abstract 1
- 239000000975 dye Substances 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 230000001105 regulatory effect Effects 0.000 abstract 1
- 230000001360 synchronised effect Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 11
- 241000588724 Escherichia coli Species 0.000 description 5
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 5
- 241000191967 Staphylococcus aureus Species 0.000 description 5
- 206010059866 Drug resistance Diseases 0.000 description 4
- 210000003491 skin Anatomy 0.000 description 4
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
- 239000004372 Polyvinyl alcohol Substances 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 210000002421 cell wall Anatomy 0.000 description 2
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 244000000010 microbial pathogen Species 0.000 description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000011896 sensitive detection Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000004544 DNA amplification Effects 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 239000004148 curcumin Substances 0.000 description 1
- 229940109262 curcumin Drugs 0.000 description 1
- 235000012754 curcumin Nutrition 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 239000002619 cytotoxin Substances 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000007140 dysbiosis Effects 0.000 description 1
- 238000010894 electron beam technology Methods 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- 229960002442 glucosamine Drugs 0.000 description 1
- MSWZFWKMSRAUBD-IVMDWMLBSA-N glucosamine group Chemical group OC1[C@H](N)[C@@H](O)[C@H](O)[C@H](O1)CO MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
- 229920000578 graft copolymer Polymers 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 230000001678 irradiating effect Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000001151 other effect Effects 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 238000002428 photodynamic therapy Methods 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 239000003642 reactive oxygen metabolite Substances 0.000 description 1
- 238000011897 real-time detection Methods 0.000 description 1
- 238000010025 steaming Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- GECHUMIMRBOMGK-UHFFFAOYSA-N sulfapyridine Chemical class C1=CC(N)=CC=C1S(=O)(=O)NC1=CC=CC=N1 GECHUMIMRBOMGK-UHFFFAOYSA-N 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 229940040944 tetracyclines Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 238000009777 vacuum freeze-drying Methods 0.000 description 1
- 229910052724 xenon Inorganic materials 0.000 description 1
- FHNFHKCVQCLJFQ-UHFFFAOYSA-N xenon atom Chemical compound [Xe] FHNFHKCVQCLJFQ-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0061—Use of materials characterised by their function or physical properties
- A61L26/0066—Medicaments; Biocides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0009—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials
- A61L26/0023—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0061—Use of materials characterised by their function or physical properties
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0061—Use of materials characterised by their function or physical properties
- A61L26/008—Hydrogels or hydrocolloids
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J3/00—Processes of treating or compounding macromolecular substances
- C08J3/02—Making solutions, dispersions, lattices or gels by other methods than by solution, emulsion or suspension polymerisation techniques
- C08J3/03—Making solutions, dispersions, lattices or gels by other methods than by solution, emulsion or suspension polymerisation techniques in aqueous media
- C08J3/075—Macromolecular gels
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
- C12Q1/18—Testing for antimicrobial activity of a material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
- G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
- G01N21/64—Fluorescence; Phosphorescence
- G01N21/6402—Atomic fluorescence; Laser induced fluorescence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/216—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials with other specific functional groups, e.g. aldehydes, ketones, phenols, quaternary phosphonium groups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
- A61L2300/62—Encapsulated active agents, e.g. emulsified droplets
- A61L2300/626—Liposomes, micelles, vesicles
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J2305/00—Characterised by the use of polysaccharides or of their derivatives not provided for in groups C08J2301/00 or C08J2303/00
- C08J2305/08—Chitin; Chondroitin sulfate; Hyaluronic acid; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2334/00—O-linked chromogens for determinations of hydrolase enzymes, e.g. glycosidases, phosphatases, esterases
- C12Q2334/20—Coumarin derivatives
- C12Q2334/22—4-Methylumbelliferyl, i.e. beta-methylumbelliferone, 4MU
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Materials Engineering (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Physics & Mathematics (AREA)
- Dispersion Chemistry (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Immunology (AREA)
- Analytical Chemistry (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Toxicology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Polymers & Plastics (AREA)
- Materials For Medical Uses (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Abstract
本发明公开了一种智能抗菌的水凝胶的制备方法及其应用。这种方法是通过使用装载有自熄性荧光染料的囊泡来实现。所述囊泡对菌体产生的关键群体密度调节的细胞毒力因子敏感,在创口有细菌感染情况下,所产生的菌体毒素可导致囊泡破裂,使染料从囊泡中释放出来,发出强烈荧光。因此可根据荧光强度的大小,可以判断创口是否被感染,进而降低被感染的风险。另外可通过在囊泡中装载光敏抗菌剂来实现对致病菌检测和杀菌的同步智能响应。本发明与传统致病菌检测方法相比,具有制备过程简单、操作方便、高效快速、准确等特点。The invention discloses a preparation method and application of an intelligent antibacterial hydrogel. This approach is achieved by using vesicles loaded with self-extinguishing fluorescent dyes. The vesicles are sensitive to the cytotoxicity factor regulated by the key population density produced by the bacteria. In the case of bacterial infection in the wound, the generated bacterial toxins can cause the rupture of the vesicles, so that the dyes are released from the vesicles and emitted. Strong fluorescence. Therefore, according to the magnitude of the fluorescence intensity, it can be determined whether the wound is infected, thereby reducing the risk of infection. In addition, the synchronous intelligent response to pathogen detection and sterilization can be achieved by loading photosensitive antimicrobial agents in vesicles. Compared with the traditional pathogenic bacteria detection method, the invention has the characteristics of simple preparation process, convenient operation, high efficiency, rapidity, accuracy and the like.
Description
技术领域technical field
本发明属生物传感技术领域,具体是一种智能抗菌的水凝胶的制备方法及其应用。The invention belongs to the technical field of biosensing, in particular to a preparation method and application of an intelligent antibacterial hydrogel.
背景技术Background technique
随着抗生素类药物在临床上的广泛应用,细菌的耐药性问题日趋严重,其耐药性不断加剧,临床多重耐药菌株的分离率相当高,其耐药机制复杂多变,给临床治疗带来极大挑战。目前致病微生物的检测及其耐药性主要通过细菌培养、生化鉴定、聚合酶链式反应扩增、实时荧光定量基因扩增技术、酶联免疫法和芯片技术等分析手段完成。上述检测手段存在着检测周期长、成本高、操作繁琐等问题,难以满足临床实时检测的需求。因此,发展快速灵敏的检测方法对于致病微生物的预防与控制等方面有着重要的现实意义。With the wide application of antibiotics in clinical practice, the problem of bacterial drug resistance is becoming more and more serious, and its drug resistance continues to intensify. The isolation rate of clinical multidrug-resistant strains is quite high. bring great challenges. At present, the detection and drug resistance of pathogenic microorganisms are mainly completed by bacterial culture, biochemical identification, polymerase chain reaction amplification, real-time fluorescent quantitative gene amplification technology, enzyme-linked immunosorbent assay and chip technology. The above detection methods have problems such as long detection period, high cost, and complicated operation, which are difficult to meet the needs of clinical real-time detection. Therefore, the development of rapid and sensitive detection methods has important practical significance for the prevention and control of pathogenic microorganisms.
创口敷料是一种覆盖在皮肤创伤上的材料,用于促进伤口愈合。水凝胶敷料是近年来发明的新型敷料,在医用敷料领域得到广泛研究与应用。有研究通过用电子束辐射聚氧化乙烯和聚乙烯醇的混合物制备了PEO/PVA接枝共聚水凝胶,并掺入了庆大霉素,研究该水凝胶的药物释放及抗菌效果。目前水凝胶成品制品负载的抗菌剂主要有纳米银、磺胺吡啶盐、姜黄素以及四环素类药物。其中纳米银抗菌水凝胶市场占有率为60%以上。有研究表明,纳米银存在很大毒性,不适用与创面。因此,抗生素类抗菌剂被广泛应用,水凝胶通过释放抗生素,用抗生素干扰细菌的重要生命过程直接将其杀死或者抑制细菌的生长来实现抗感染的目的,但由于细菌本身具有快速适应性和进化能力,极其容易产生耐药性和微生物菌群失调等负面作用。因此有必要采用一种有效并且不易产生耐药性的方法来替代或者辅助抗生素的治疗。光动力抗菌疗法(photonamic antimicrobial chemotherapy,PACT)是近几年出现的最具有前景的疗法之一。PACT抗菌作用原理是光敏剂选择性聚集于细菌细胞壁和细胞膜上,在适当波长光源的激发下,依靠氧的参与,通过I型、II型反应产生单线态氧等活性氧物质,直接破细菌细胞壁和膜系统,影响其新陈代谢,进而导致细菌死亡。PACT抗菌作用不仅能有效杀伤致病菌,还能灭活细菌毒素因子,具备有效杀伤致病菌而不易产生耐受的独特优势。A wound dressing is a material that covers a wound on the skin to promote wound healing. Hydrogel dressing is a new type of dressing invented in recent years, which has been widely researched and applied in the field of medical dressing. Some studies have prepared PEO/PVA graft copolymer hydrogel by irradiating the mixture of polyethylene oxide and polyvinyl alcohol with electron beam, and incorporated gentamicin to study the drug release and antibacterial effect of the hydrogel. At present, the antibacterial agents loaded in the finished hydrogel products mainly include nano-silver, sulfapyridine salts, curcumin and tetracyclines. Among them, the market share of nano-silver antibacterial hydrogel is more than 60%. Studies have shown that nano-silver has great toxicity and is not suitable for wounds. Therefore, antibiotic antibacterial agents are widely used. Hydrogels achieve the purpose of anti-infection by releasing antibiotics, interfering with the important life process of bacteria with antibiotics, directly killing them or inhibiting the growth of bacteria. However, due to the rapid adaptability of bacteria themselves and evolutionary ability, it is extremely prone to negative effects such as drug resistance and microbial dysbiosis. Therefore, it is necessary to use an effective and less resistant method to replace or supplement antibiotic therapy. Photonamic antimicrobial chemotherapy (PACT) is one of the most promising treatments in recent years. The antibacterial action principle of PACT is that the photosensitizer selectively accumulates on the bacterial cell wall and cell membrane. Under the excitation of the appropriate wavelength light source, relying on the participation of oxygen, reactive oxygen species such as singlet oxygen are generated through the type I and type II reactions, which directly destroy the bacterial cell wall. and membrane system, affecting its metabolism, which in turn leads to bacterial death. The antibacterial effect of PACT can not only effectively kill pathogenic bacteria, but also inactivate bacterial toxin factors, which has the unique advantage of effectively killing pathogenic bacteria without easily developing tolerance.
基于上述问题,我们设计了一种具有检测细菌微生物并智能杀菌的水凝胶敷料,其中通过使用装载有自熄性荧光染料的囊泡来实现对病原菌的智能检测,另外可通过在囊泡中装载光敏抗菌剂来实现对致病菌检测和杀菌的同步智能响应。Based on the above problems, we designed a hydrogel dressing capable of detecting bacterial microorganisms and intelligently sterilizing, in which the intelligent detection of pathogenic bacteria is realized by using vesicles loaded with self-extinguishing fluorescent dyes, and the Loaded with photosensitive antibacterial agents to achieve simultaneous intelligent response to pathogen detection and sterilization.
发明内容SUMMARY OF THE INVENTION
本发明的目的是提供一种智能抗菌的水凝胶的制备方法及其应用。The purpose of the present invention is to provide a preparation method and application of an intelligent antibacterial hydrogel.
本发明解决上述技术问题的技术方案如下:The technical scheme that the present invention solves the above-mentioned technical problems is as follows:
1.一种智能抗菌的水凝胶的制备方法,操作步骤如下:1. a preparation method of an intelligent antibacterial hydrogel, the operation steps are as follows:
1)称取73.4mg磷脂1,2-二棕榈酰-Sn-甘油-3-磷酸胆碱(DPPC),38.6mg胆固醇和34.6mg10,12-二十三碳二烯酸(TCDA)分别溶解在1mL的氯仿中,浓度为100mmol/dm3。取660μL DPPC,240μL胆固醇和300μL TCDA在氮气流中混合,然后干燥、除杂和脱水。1) Weigh 73.4 mg of phospholipid 1,2-dipalmitoyl-Sn-glycero-3-phosphocholine (DPPC), 38.6 mg of cholesterol and 34.6 mg of 10,12-tricosadadienoic acid (TCDA) and dissolved in In 1 mL of chloroform, the concentration was 100 mmol/dm 3 . 660 μL of DPPC, 240 μL of cholesterol and 300 μL of TCDA were taken and mixed in nitrogen flow, followed by drying, impurity removal and dehydration.
2)将含有50mmol/dm3荧光剂的10mL缓冲液和脂质混合,冷冻循环,最后通过聚碳酸酯膜用囊泡挤出机将脂质混合物挤出,在4℃下储存囊泡备用。2) Mix 10 mL of buffer containing 50 mmol/dm 3 fluorescent agent and lipid, freeze and circulate, and finally extrude the lipid mixture through a polycarbonate membrane with a vesicle extruder, and store the vesicles at 4°C for later use.
3)制作尺寸为90×90×1mm3的水凝胶敷料,水凝胶上嫁接4-甲基伞形酮基-α-D-甘露糖苷(MUD),致病菌释放的酶能剪切MUD荧光剂,将荧光团4-甲基伞形酮(4-MU)释放到水凝胶中,在紫外灯(λ=365nm)下呈现蓝光。将制备好的水凝胶敷料的刻有均匀间隔的圆柱形小孔,每个小孔具有均匀的直径和深度。 3 ) A hydrogel dressing with a size of 90 × 90 × 1 mm is made, and 4-methylumbelliferyl-α-D-mannoside (MUD) is grafted on the hydrogel, and the enzymes released by pathogenic bacteria can cut The MUD fluorophore, which releases the fluorophore 4-methylumbelliferone (4-MU) into the hydrogel, exhibits blue light under UV light (λ=365 nm). The prepared hydrogel dressing is engraved with evenly spaced cylindrical pores, each of which has a uniform diameter and depth.
4)囊中的填充物为囊泡、致病菌检测荧光剂和壳聚糖,此荧光剂不仅能检测致病菌而且能在自然光照的条件下起到灭菌的作用,主要的抗菌光敏剂有金丝桃素等天然光敏抗菌剂。4) The fillings in the capsule are vesicles, pathogenic bacteria detection fluorescent agent and chitosan. This fluorescent agent can not only detect pathogenic bacteria but also play a role in sterilization under natural light conditions. The main antibacterial photosensitizer There are natural photosensitive antibacterial agents such as hypericin.
2.一种智能抗菌的水凝胶的应用:应用于致病菌的检测、智能抗菌实验和智能光敏抗菌剂对小鼠伤口愈合的影响。2. Application of an intelligent antibacterial hydrogel: applied to the detection of pathogenic bacteria, intelligent antibacterial experiments and the effect of intelligent photosensitizing antibacterial agents on wound healing in mice.
由于采用以上技术方案,本发明的检测且抗菌作用的智能创可贴敷料的制备方法,其有利技术效果是:Due to the adoption of the above technical solutions, the method for preparing an intelligent Band-Aid dressing with detection and antibacterial effect of the present invention has the following advantageous technical effects:
1.本发明制备抗菌水凝胶敷料的原料主要是壳聚糖。壳聚糖的结构与性质相似于细胞外基质;生物相容性好,不与人体组织发生排斥反应;壳聚糖还有良好的生物活性,具有抑菌,降低胆固醇等功效,还可以促进上皮细胞生长;壳聚糖可在溶菌酶的存在下发生降解,降解过程平缓安全,降解产物为葡萄胺,可直接进入代谢途径。1. The raw material of the present invention to prepare the antibacterial hydrogel dressing is mainly chitosan. The structure and properties of chitosan are similar to the extracellular matrix; it has good biocompatibility and does not react with human tissues; chitosan also has good biological activity, with antibacterial, cholesterol-lowering and other effects, and can also promote epithelial Cell growth; chitosan can be degraded in the presence of lysozyme, the degradation process is smooth and safe, and the degradation product is glucosamine, which can directly enter the metabolic pathway.
2.本发明的囊内填充物主要是囊泡、致病菌检测荧光剂和壳聚糖,囊内的荧光剂主要是天然提取物,此荧光剂不仅能对致病菌进行检测而且在自然光下能起到杀菌的作用,本发明实现了创口致病菌的检测与治疗实现同步进行。2. The fillings in the capsules of the present invention are mainly vesicles, pathogenic bacteria detection fluorescent agents and chitosan, and the fluorescent agents in the capsules are mainly natural extracts, which can not only detect pathogenic bacteria but also detect pathogenic bacteria in natural light. It can play the role of sterilization, and the invention realizes the simultaneous detection and treatment of the pathogenic bacteria in the wound.
3.本发明在制备上所用的试剂都是无毒副作用,制备的水凝胶敷料生物相容性良好。3. The reagents used in the preparation of the present invention are all non-toxic and side effects, and the prepared hydrogel dressing has good biocompatibility.
附图说明Description of drawings
图1是溶液中的酶促反应效果图。Figure 1 is a diagram of the effect of the enzymatic reaction in solution.
图中,A、B、C分别是铜绿假单胞菌、大肠杆菌、金黄色葡萄球菌。In the figure, A, B, and C are Pseudomonas aeruginosa, Escherichia coli, and Staphylococcus aureus, respectively.
图2是水凝胶敷料上酶促反应效果图。Figure 2 is a diagram showing the effect of enzymatic reaction on the hydrogel dressing.
图中,A、B、C分别是铜绿假单胞菌、大肠杆菌、金黄色葡萄球菌。In the figure, A, B, and C are Pseudomonas aeruginosa, Escherichia coli, and Staphylococcus aureus, respectively.
图3是智能水凝胶伤口敷料在紫外灯下检测致病菌的效果图。Figure 3 shows the effect of the smart hydrogel wound dressing on the detection of pathogenic bacteria under UV light.
图中,左图是未应用时的图;右图是应用后的效果图。In the figure, the left picture is the picture before application; the right picture is the effect picture after application.
图4是金丝桃素抗菌效果图。Figure 4 is a graph showing the antibacterial effect of hypericin.
图中,A、B、C、D光动力治疗组、只有光敏剂组、只有氙灯照射组和空白对照组。In the figure, A, B, C, D photodynamic therapy group, only photosensitizer group, only xenon lamp irradiation group and blank control group.
图5是本发明动物实验实验组和对照组小鼠表皮组织学对比图。Figure 5 is a histological comparison diagram of the mouse epidermis between the experimental group of the animal experiment of the present invention and the control group.
图中,A、B、C分别是正常小鼠、光照组、不光照组。In the figure, A, B, and C are normal mice, light group, and no light group, respectively.
具体实施方案specific implementation
下面结合实施例对本发明进行进一步的详细说明。以下为本发明的实施示例,并不用以限制本发明,凡在本发明的基础上,所做的任何修改、替换和改进等,均包含在本发明的保护范围之内。The present invention will be further described in detail below in conjunction with the examples. The following are examples of implementations of the present invention, which are not intended to limit the present invention, and any modifications, substitutions and improvements made on the basis of the present invention are included within the protection scope of the present invention.
实施例1.一种智能抗菌的水凝胶Embodiment 1. A kind of intelligent antibacterial hydrogel
利用智能抗菌的水凝胶在致病菌的检测的应用,操作步骤如下:The application of intelligent antibacterial hydrogel in the detection of pathogenic bacteria, the operation steps are as follows:
1.溶液中酶促反应1. Enzymatic reaction in solution
对于溶液中的酶促反应,将50μL MUD溶液加入到装有50μL菌液的96孔板中,将96孔板用封口胶带封好,放到荧光池中观察荧光强度如图1所示。For the enzymatic reaction in solution, add 50 μL of MUD solution to a 96-well plate containing 50 μL of bacterial solution, seal the 96-well plate with sealing tape, and place it in a fluorescent cell to observe the fluorescence intensity as shown in Figure 1.
2.水凝胶敷料在培养皿上的酶促反应2. Enzymatic Reaction of Hydrogel Dressing on Petri Dish
在制备好的水凝胶敷料表面嫁接50μL MUD溶液,然后放到涂有50μL菌液的培养皿上,观察水凝胶敷料的发光强度如图2所示。50 μL of MUD solution was grafted on the surface of the prepared hydrogel dressing, and then placed on a petri dish coated with 50 μL of bacterial solution, and the luminescence intensity of the hydrogel dressing was observed as shown in Figure 2.
3.金丝桃素包合物的制备3. Preparation of Hypericin Inclusion Complex
将5.0gβ-CD(β-环糊精)加入10ml 30%NaOH溶液中,室温搅拌使β-CD溶解。在30℃下将2.41ml的EP加入上述混合溶液,搅拌24h,冷却至室温。透析法除盐,将透析袋中的溶液蒸至粘稠状,加入无水乙醇,有白色固体析出,将白色固体过滤,真空冷冻干燥,既得到β-CDP(β-环糊精聚合物)。将80mg的β-CDP和10mg的Hyp(金丝桃素)溶解在适量的水中,室温下充分搅拌至少24h。反应结束后,将混合溶液过滤,移除剩余的Hyp,得到了含有包合复合物的深紫色溶液,真空冷冻干燥得深紫色产品Hyp-β-CDP(金丝桃素包合物)。5.0 g of β-CD (β-cyclodextrin) was added to 10 ml of 30% NaOH solution, and the β-CD was dissolved by stirring at room temperature. 2.41ml of EP was added to the above mixed solution at 30°C, stirred for 24h, and cooled to room temperature. Desalting by dialysis, steaming the solution in the dialysis bag to a viscous state, adding absolute ethanol, a white solid is precipitated, filtering the white solid, and vacuum freeze drying to obtain β-CDP (β-cyclodextrin polymer) . Dissolve 80 mg of β-CDP and 10 mg of Hyp (hypericin) in an appropriate amount of water, and stir well at room temperature for at least 24 h. After the reaction, the mixed solution was filtered to remove the remaining Hyp to obtain a dark purple solution containing an inclusion complex, which was vacuum freeze-dried to obtain a dark purple product Hyp-β-CDP (hypericin inclusion complex).
4.金丝桃素包合物填充至囊泡中4. Inclusion of hypericin into vesicles
在水凝胶均匀制备若干个圆孔,孔中添加囊泡和壳聚糖,其中囊泡内的填充物为金丝桃素包合物或者其他天然光敏抗菌剂。Several round holes are uniformly prepared in the hydrogel, vesicles and chitosan are added in the holes, and the filling in the vesicles is hypericin inclusion complex or other natural photosensitive antibacterial agent.
实验结果Experimental results
图1中的A、B、C分别是铜绿假单胞菌、大肠杆菌、金黄色葡萄球菌在96孔板里的酶促反应,酶促反应1h,从荧光强度来判断,荧光底物MUD对这三种菌都会荧光,说明荧光底物MUD对这三种菌具有一定检测作用;图2中A、B、C培养皿上分别是铜绿假单胞菌、大肠杆菌、金黄色葡萄球菌,将水凝胶敷料切成大小为1.5cm×1.5cm的正方形,将荧光底物嫁接到水凝胶敷料上,再将敷料放置于培养皿上,酶促反应1h,从图中的荧光强度来看,此敷料对这三种菌都有检测作用;图3是紫外灯下辅料被激活前后对比图,从图种可以看出致病菌释放的毒素使囊泡裂解,金丝桃素被释放出来,在紫外灯(λ=365nm)下呈现红色的荧光。A, B, and C in Figure 1 are the enzymatic reactions of Pseudomonas aeruginosa, Escherichia coli, and Staphylococcus aureus in a 96-well plate respectively. The enzymatic reaction is 1 h. Judging from the fluorescence intensity, the fluorescent substrate MUD has These three bacteria will fluoresce, indicating that the fluorescent substrate MUD has a certain detection effect on these three bacteria; in Figure 2, Pseudomonas aeruginosa, Escherichia coli, and Staphylococcus aureus are on the culture dishes A, B, and C, respectively. The hydrogel dressing was cut into squares with a size of 1.5cm×1.5cm, and the fluorescent substrate was grafted onto the hydrogel dressing, and then the dressing was placed on a petri dish, and the enzymatic reaction was carried out for 1h. From the fluorescence intensity in the figure , this dressing has a detection effect on these three kinds of bacteria; Figure 3 is the comparison picture before and after the excipients are activated under the ultraviolet lamp. It can be seen from the picture that the toxin released by the pathogenic bacteria causes the vesicles to crack, and the hypericin is released. , showing red fluorescence under UV lamp (λ=365nm).
实施例2Example 2
利用智能抗菌的水凝胶在智能抗菌实验的应用,操作步骤如下:The application of intelligent antibacterial hydrogel in intelligent antibacterial experiment, the operation steps are as follows:
1.细菌培养1. Bacterial culture
从LB平板上挑取细菌,放在50ml的离心管中,离心管中加10ml的LB培养液,放在37℃的摇床中培养15h,待用。Pick bacteria from the LB plate, put them in a 50ml centrifuge tube, add 10ml of LB culture medium to the centrifuge tube, and culture in a shaker at 37°C for 15h until use.
2.固体培养基的制作2. Preparation of solid medium
取1000ml烧杯,放入500ml的蒸馏水,称取5g牛肉膏,10g蛋白胨,5g琼脂,5g氯化钠溶解在水中,用10%NaOH溶液调节pH至7.2左右,并定容到1000ml,用锡箔纸包好,放在灭菌箱中灭菌,备用。Take a 1000ml beaker, put it in 500ml of distilled water, weigh 5g of beef extract, 10g of peptone, 5g of agar, and 5g of sodium chloride and dissolve it in water, adjust the pH to about 7.2 with 10% NaOH solution, and set the volume to 1000ml. Packed and sterilized in a sterilization box for later use.
3.抗菌实验3. Antibacterial test
将培养好的菌种用LB溶液稀释10倍,测OD600值,再将菌种稀释到0.01,待用。取出96孔板,加入菌液和光敏抗菌剂,在37℃的培养箱中孵化1h,将其中的一组光照30min,另一组避光处理30min;光照后将96孔板里的溶液涂布在固体培养皿中,然后在37℃下培养12h;取出培养皿,观察培养皿中细菌的生长情况。Dilute the cultured strains 10 times with LB solution, measure the OD 600 value, and then dilute the strains to 0.01 for use. Take out the 96-well plate, add bacterial solution and photosensitizing antibacterial agent, incubate for 1 h in a 37°C incubator, expose one group to light for 30 minutes, and treat the other group to avoid light for 30 minutes; after lighting, apply the solution in the 96-well plate to In a solid petri dish, then cultured at 37°C for 12 h; take out the petri dish and observe the growth of bacteria in the petri dish.
实验结果Experimental results
图4中A、B是在囊泡中添加了光敏抗菌剂,在有无光照的情况下细菌的生长情况。从图中很明显可以看出来在有光照的情况下,细菌没有生长;无光照的情况,细菌已经长满整个培养皿。In Figure 4, A and B are the growth of bacteria in the presence or absence of light when photosensitive antimicrobial agents are added to the vesicles. It is obvious from the figure that in the case of light, the bacteria did not grow; in the absence of light, the bacteria have overgrown the entire petri dish.
图4中C、D是在囊泡中没有添加光敏抗菌剂,在有无光照的情况下细菌的生长情况。从图中可以观察到,无论是否光照,培养皿上都长满了细菌。C and D in Figure 4 show the growth of bacteria in the presence or absence of light without adding photosensitizing antibacterial agents to the vesicles. From the picture, it can be observed that the petri dishes are covered with bacteria with or without light.
实施例3Example 3
利用智能抗菌的水凝胶在智能光敏抗菌剂对小鼠伤口愈合的影响的应用,操作步骤如下:The application of smart antibacterial hydrogel in the effect of smart photosensitizing antibacterial agent on wound healing in mice, the operation steps are as follows:
1实验材料1 Experimental material
1.1实验试剂1.1 Experimental reagents
金丝桃素或天然光敏抗菌剂提取物,医用酒精,稀释的菌液Hypericin or natural photosensitive antibacterial agent extract, medical alcohol, diluted bacterial liquid
1.2实验动物1.2 Experimental animals
昆明小鼠Kunming mice
2实验方法2 Experimental methods
2.1小鼠创口模型制作2.1 Making a mouse wound model
取健康的小鼠,使用乌拉坦将其麻醉后,取干净的剪刀,除去小鼠毛发,将去毛的地方用医用酒精消毒后,再用消毒过的剪刀和镊子在小鼠背部制作面积大约为1cm2创口模型。Take a healthy mouse, anesthetize it with urethane, take clean scissors, remove the mouse hair, sterilize the hair removal area with medical alcohol, and then use the sterilized scissors and tweezers to make an area on the back of the mouse about approx. For the 1cm2 wound model.
2.2分组与给药2.2 Grouping and Administration
将小鼠分为实验组、对照组,每组10只小鼠,实验组在其小鼠伤口处涂菌和放置含有光敏抗菌剂的智能水凝胶,对照组在其伤口只涂布菌,不做其他处理。实验对小鼠的伤口进行光照1h,然后观察记录小鼠伤口的愈合情况。实验第7天对小鼠伤口皮肤进行组织学检查。The mice were divided into an experimental group and a control group, with 10 mice in each group. The experimental group applied bacteria to the wounds of the mice and placed smart hydrogels containing photosensitizing antibacterial agents, while the control group only applied bacteria to the wounds. Do not do other processing. The wounds of the mice were illuminated for 1 h, and then the wound healing of the mice was observed and recorded. On the seventh day of the experiment, the mouse wound skin was histologically examined.
2.3组织学分析2.3 Histological analysis
将所取皮肤放在4%的福尔马林里浸泡24h,皮肤组织经常规漂洗、脱水、透明、浸蜡、包埋后,制作蜡块切片,用切片机切片(厚度为3-5μm);使用烘箱烘干2-3h,用二甲苯脱蜡处理5min(共4次),洗去二甲苯;刮掉苏木素表面氧化镁,对其进行染色;将上述脱蜡后的的切片放苏木素中染色5min,用自来水洗三次,用1%盐酸酒精分化液分化,将切片放水里浸泡5-10min,用伊红染液浸泡切片30s,在显微镜下观察颜色,颜色若浅,则加长浸泡时间,将切片放95%酒精中泡一下,放烘箱里晾干,用中性树胶滴2滴,盖上盖玻片,晾干过夜。The taken skin was soaked in 4% formalin for 24 hours, and the skin tissue was routinely rinsed, dehydrated, transparent, dipped in wax, and embedded to make a wax block section, which was sliced with a microtome (thickness of 3-5 μm). Use an oven to dry for 2-3h, dewax with xylene for 5min (4 times in total), wash away xylene; scrape off the magnesia on the surface of hematoxylin, and stain it; put the above-mentioned dewaxed section in hematoxylin Stain for 5 min, wash three times with tap water, differentiate with 1% hydrochloric acid alcohol differentiation solution, soak the sections in water for 5-10 min, soak the sections in eosin staining solution for 30 s, observe the color under a microscope, if the color is light, then prolong the soaking time, Soak the sections in 95% alcohol, put them in an oven to dry, add 2 drops of neutral gum, cover with a cover glass, and let dry overnight.
2.4实验结果2.4 Experimental results
图5是小鼠伤口组织学切片,A是没有被菌感染的正常小鼠切片,B被菌液感染后加光敏抗菌剂的光照组,C被菌液感染后加光敏抗菌剂的不光照组。从显微镜下观察到:B含有少量的淋巴细胞,C出现大量淋巴细胞,从而说明光敏抗菌剂在光照条件下能起到杀菌作用。Figure 5 shows the histological sections of mouse wounds, A is a normal mouse section that was not infected with bacteria, B was a light group with photosensitizing antibacterial agents added after being infected with bacterial liquid, and C was a non-illuminated group with photosensitizing antibacterial agents added after being infected with bacterial liquid . Observed from the microscope: B contains a small amount of lymphocytes, C has a large number of lymphocytes, which indicates that the photosensitizing antibacterial agent can play a bactericidal effect under light conditions.
综上所述,本发明是一种具有检测且抗菌作用的创口贴敷料,通过对铜绿假单胞菌、大肠杆菌、金黄色葡萄球菌这三种常见致病菌进行酶促反应,根据是否发出荧光及其荧光信号的强弱,实现对这三种常见致病菌的实时高效灵敏的检测。将金丝桃素等天然光敏抗菌剂填充到囊泡内,病原菌产生的细胞毒素会导致囊泡裂解的响应,使得光敏抗菌剂从囊泡中释放出来,实现了对致病菌的智能检测和治疗的同步进行。To sum up, the present invention is a wound dressing with detection and antibacterial effect, by carrying out enzymatic reaction on three common pathogenic bacteria of Pseudomonas aeruginosa, Escherichia coli and Staphylococcus aureus, according to whether the The intensity of fluorescence and its fluorescence signal enables real-time, efficient and sensitive detection of these three common pathogenic bacteria. When natural photosensitive antibacterial agents such as hypericin are filled into the vesicles, the cytotoxins produced by pathogenic bacteria will cause the response of vesicle lysis, so that the photosensitive antibacterial agents are released from the vesicles, realizing intelligent detection and detection of pathogenic bacteria. Synchronization of treatment.
Claims (4)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201911074386.XA CN110743035A (en) | 2019-11-06 | 2019-11-06 | Preparation method and application of intelligent antibacterial hydrogel |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201911074386.XA CN110743035A (en) | 2019-11-06 | 2019-11-06 | Preparation method and application of intelligent antibacterial hydrogel |
Publications (1)
Publication Number | Publication Date |
---|---|
CN110743035A true CN110743035A (en) | 2020-02-04 |
Family
ID=69282363
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201911074386.XA Pending CN110743035A (en) | 2019-11-06 | 2019-11-06 | Preparation method and application of intelligent antibacterial hydrogel |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN110743035A (en) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112011589A (en) * | 2020-08-18 | 2020-12-01 | 北京诺康达医药科技股份有限公司 | Pathogenic microorganism color developing agent and preparation method and application thereof |
CN113144280A (en) * | 2021-03-31 | 2021-07-23 | 温州医科大学慈溪生物医药研究院 | Intelligent antibacterial hydrogel and application thereof |
CN115850735A (en) * | 2022-12-13 | 2023-03-28 | 华南理工大学 | A temperature-sensitive self-modeling stretchable hyaluronic acid/β-cyclodextrin hydrogel and its preparation method and application |
CN116194078A (en) * | 2020-09-10 | 2023-05-30 | 益生生物科技有限公司 | Pharmaceutical composition comprising orange-derived extracellular vesicles in the form of a hydrogel |
CN119405875A (en) * | 2024-10-31 | 2025-02-11 | 安徽中科生命谷科技有限公司 | Plant polysaccharide hydrogel medical dressing for promoting tissue damage repair and its application |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU7521796A (en) * | 1995-10-25 | 1997-05-15 | Eoe, Inc. | Microporous pathogen-killing composition |
CN102573800A (en) * | 2009-08-10 | 2012-07-11 | 台湾微脂体股份有限公司 | Ocular Drug Delivery System Containing Phospholipids and Cholesterol |
CN107469140A (en) * | 2017-08-14 | 2017-12-15 | 高鼎精细化工(昆山)有限公司 | A kind of photodynamics antiseptic dressing for having antibacterial functions, preparation method and application |
CN107823695A (en) * | 2017-09-19 | 2018-03-23 | 华东理工大学 | A kind of intelligent antiseptic dressing and preparation method thereof |
CN109453408A (en) * | 2018-11-16 | 2019-03-12 | 江南大学 | Antibacterial wound dressing and preparation method thereof |
-
2019
- 2019-11-06 CN CN201911074386.XA patent/CN110743035A/en active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU7521796A (en) * | 1995-10-25 | 1997-05-15 | Eoe, Inc. | Microporous pathogen-killing composition |
CN102573800A (en) * | 2009-08-10 | 2012-07-11 | 台湾微脂体股份有限公司 | Ocular Drug Delivery System Containing Phospholipids and Cholesterol |
CN107469140A (en) * | 2017-08-14 | 2017-12-15 | 高鼎精细化工(昆山)有限公司 | A kind of photodynamics antiseptic dressing for having antibacterial functions, preparation method and application |
CN107823695A (en) * | 2017-09-19 | 2018-03-23 | 华东理工大学 | A kind of intelligent antiseptic dressing and preparation method thereof |
CN109453408A (en) * | 2018-11-16 | 2019-03-12 | 江南大学 | Antibacterial wound dressing and preparation method thereof |
Non-Patent Citations (2)
Title |
---|
MIR-MORTEZA, ET AL: "Autonomously Sensing Hydrogels for the Rapid and Selective Detection of Pathogenic Bacteria", 《MACROMOLECULAR RAPID COMMUNICATIONS》 * |
肖冬梅等: "金丝桃素对铜绿假单胞菌的体外光动力杀菌研究", 《广东大学学报(自然科学报)》 * |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112011589A (en) * | 2020-08-18 | 2020-12-01 | 北京诺康达医药科技股份有限公司 | Pathogenic microorganism color developing agent and preparation method and application thereof |
CN112011589B (en) * | 2020-08-18 | 2022-07-01 | 北京诺康达医药科技股份有限公司 | Pathogenic microorganism color developing agent and preparation method and application thereof |
CN116194078A (en) * | 2020-09-10 | 2023-05-30 | 益生生物科技有限公司 | Pharmaceutical composition comprising orange-derived extracellular vesicles in the form of a hydrogel |
CN113144280A (en) * | 2021-03-31 | 2021-07-23 | 温州医科大学慈溪生物医药研究院 | Intelligent antibacterial hydrogel and application thereof |
CN115850735A (en) * | 2022-12-13 | 2023-03-28 | 华南理工大学 | A temperature-sensitive self-modeling stretchable hyaluronic acid/β-cyclodextrin hydrogel and its preparation method and application |
CN119405875A (en) * | 2024-10-31 | 2025-02-11 | 安徽中科生命谷科技有限公司 | Plant polysaccharide hydrogel medical dressing for promoting tissue damage repair and its application |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN110743035A (en) | Preparation method and application of intelligent antibacterial hydrogel | |
Al-Waili | Investigating the antimicrobial activity of natural honey and its effects on the pathogenic bacterial infections of surgical wounds and conjunctiva | |
JP4481372B2 (en) | Bactericidal plastic sponge material | |
Wang et al. | Wound therapy via a photo-responsively antibacterial nano-graphene quantum dots conjugate | |
CN104857551B (en) | A kind of silver-containing antibacterial dressing and preparation method | |
Xiong et al. | Derma-like antibacterial polysaccharide gel dressings for wound care | |
Hafner et al. | Photodynamic inactivation of Actinomyces naeslundii in comparison with chlorhexidine and polyhexanide—a new approach for antiseptic treatment of medication-related osteonecrosis of the jaw? | |
Huang et al. | Evaluation of the Xanthan‐Based Film Incorporated with Silver Nanoparticles for Potential Application in the Nonhealing Infectious Wound | |
Pati et al. | Antibiofilm activity of chitosan/epsilon‐poly‐L‐lysine hydrogels in a porcine ex vivo skin wound polymicrobial biofilm model | |
CN111150876B (en) | Band-aid for drug resistance visualization and preparation method thereof | |
Wojcik et al. | Biocompatible curdlan-based biomaterials loaded with gentamicin and Zn-doped nano-hydroxyapatite as promising dressing materials for the treatment of infected wounds and prevention of surgical site infections | |
Wang et al. | Continuous and controllable electro-fabrication of antimicrobial copper-alginate dressing for infected wounds treatment | |
Tian et al. | Ferrihydrite nanoparticles as the photosensitizer augment microbial infected wound healing with blue light | |
Mothilal et al. | Amikacin sulphate loaded chitosan-diopside nanoparticles composite scaffold for infectious wound healing | |
Fan et al. | A peptide-based pH-sensitive antibacterial hydrogel for healing drug-resistant biofilm-infected diabetic wounds | |
CN113908127B (en) | A vesicle for treating diseases caused by helicobacter pylori | |
Liu et al. | Dual-acting antibacterial porous chitosan film embedded with a photosensitizer | |
Carvalho et al. | Photodynamic inactivation of in vitro bacterial cultures from pressure ulcers | |
CN111494304B (en) | Polysaccharide-based hybrid hydrogel and construction method and application thereof | |
Parmar et al. | Antimicrobial study of chitosan-based crosslinked hydrogel against Staphylococcus aureus, Porphyromonas gingivalis, Pseudomonas aeruginosa, and Streptococcus mutans | |
Wen et al. | Natural fluorescent carbon quantum dots embedded polyvinyl alcohol/chitosan film with photoregulation and high antibacterial efficiency for infected wound healing | |
CN116115640A (en) | Preparation method and application of nano material containing metal ions | |
Al-Akhras et al. | Modeling the effect of rose bengal on growth and decay patterns of Pseudomonas aeruginosa, Escherichia coli and Staphylococcus aureus | |
CN114617964A (en) | Enzyme-responsive photo-thermal nano material G @ CuS and preparation method thereof | |
CN115227817A (en) | A laser-driven BBR@SP bioactive hydrogel, preparation method and use |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
WD01 | Invention patent application deemed withdrawn after publication | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20200204 |